(Oslo, 8th of June 2021) Medistim ASA (OSE: MEDI) is a niche market leader
within ultrasound technology with headquarters in Oslo, Norway. Medistim
develops and commercializes medical equipment for use within cardiac, vascular
and transplant surgery. Today, Medistim announces the launch of the Pay Per
Procedure (PPP) functionality to our latest MiraQTM platform in the US market. 

Medistim utilizes several business models to effectively reach different
segments of the US market. In addition to traditional capital investments and
purchase of consumables, hospitals can choose to enter leasing agreements or Pay
Per Procedure (PPP). The PPP functionality has proven to be a popular option
with our previous generation of medical device (VeriQTM and VeriQCTM and will
now also be available to our MiraQ customers. 

"Some of our largest customers in the USA are greatly appreciating the PPP model
with their current VeriQTM platform and Medistim wants to make their transition
to the latest platform MiraQTM as smooth as possible," says Medistim President
and CEO, Kari E. Krogstad.  "The US market is key to Medistim's success, making
up about 1/3 of the global potential market, and it is our priority to respond
to our customers' preferences."

About Medistim:
Medistim was established in 1984 and has a track record of profitable growth
over the past 20 years.  The company is a pioneer within its segment and
continues to invest in new product development.  Medistim has wholly owned
subsidiaries with sales organizations in the USA, Germany, UK, Spain, Denmark,
and Norway, in addition to the about 50 distributors in Europe, Asia, Middle
East, Africa, Canada and South America.   For more information, visit the
Medistim home page:  www.medistim.com 

For more information, contact: 

President and CEO, Kari E. Krogstad, Medistim ASA 
Tel: + 47 918 38 110  
Email: kari.krogstad@medistim.com 

CFO, Thomas Jakobsen, Medistim ASA
Tel: + 47 906 59 940  
Email: thomas.jakobsen@medistim.com